Application of astragaloside in preparation of medicine for treating oligoasthenospermia and medicine

Abstract

The invention relates to application of astragaloside in preparing a medicine for treating oligoasthenospermia and the medicine, and belongs to the field of traditional Chinese medicines. Animal experiments show that the astragaloside remarkably improves the quantity and quality of sperms of rats, and no obvious side effect is observed in the treatment process. The astragaloside has the effects of inhibiting oxidative stress reaction, promoting secretion of testosterone and regulating secretion of follicle-stimulating hormone and luteinizing hormone, and also can promote growth and maturation of sperms, effectively improve sperm functions and enhance repair capacity of an organism to testis injury. And the astragaloside has no obvious side effect in the process of treating oligoasthenospermia.

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to the application of astragaloside IV in preparing a drug for treating oligoasthenospermia and a drug. Background Art

[0002] Oligozoospermia is a common symptom of male infertility, which refers to the number of sperm in male semen being lower than normal, or the sperm motility being poor, or the sperm morphology being abnormal. Oligozoospermia is one of the important causes of male infertility. The causes of oligozoospermia are varied, and may include genetic factors, environmental pollution, lifestyle, endocrine disorders, oxidative stress and other factors. At present, the treatment methods for oligozoospermia mainly rely on hormone replacement therapy, drug therapy, assisted reproductive technology (such as artificial insemination, in vitro fertilization, etc.), etc. Among them, hormone therapy, also known as hormone replacement therapy (such as testosterone replacement therapy), is a common method in the treatment of oligozoospermia. This method improves the sperm production process by regulating the hormone levels in the body, and is usually used for oligozoospermia caused by endocrine disorders. However, hormone therapy often causes side effects, such as sexual dysfunction, weight gain, mood swings, etc., and its effects are often temporary, and symptoms may recur after treatment is stopped. Antioxidant therapy: Since oxidative stress is one of the main causes of decreased sperm quality, many studies have attempted to use antioxidants (such as vitamin C, vitamin E, selenium, etc.) to improve sperm quality. Although antioxidants can reduce the production of free radicals, their effectiveness varies greatly from individual to individual, and long-term use may cause some side effects, such as gastrointestinal discomfort. Although assisted reproductive technology is effective, the treatment process is cumbersome and expensive, and there is a certain failure rate, and it cannot fundamentally improve the sperm production process. Therefore, finding a natural medicine that can both improve sperm quantity and quality and have fewer side effects has become an important research direction for solving the problem of oligoasthenozoospermia.

[0003] In the field of traditional Chinese medicine, Astragalus membranaceus, as a traditional medicinal material, has a wide range of pharmacological activities, including strengthening the spleen and replenishing the middle, raising yang and lifting the sunken, strengthening the body's defense and strengthening the exterior, diuresis, and expelling toxins and promoting tissue regeneration. It is mainly used to treat spleen qi deficiency syndrome, lung qi deficiency syndrome, qi deficiency and spontaneous sweating syndrome, qi and blood deficiency, ulcers that are difficult to ulcerate or ulcers that are difficult to heal. Astragaloside IV, one of the active ingredients in Astragaloside, is used as a standard for evaluating the quality of Astragaloside. It has the effects of enhancing the body's immune function, strengthening the heart and lowering blood pressure, lowering blood sugar, diuresis, anti-aging, and anti-fatigue. At present, there is no research specifically on Astragaloside IV for the treatment of oligoasthenospermia, especially no systematic clinical or experimental research to explore its mechanism and efficacy. Summary of the invention

[0004] In view of the above problems, the present invention provides the use of astragaloside IV for preparing a drug for treating oligoasthenospermia and a drug.

[0005] The first object of the present invention is to provide the use of astragaloside IV for preparing a drug for treating oligoasthenospermia.

[0006] Furthermore, the oligoasthenozoospermia is caused by a pathogen.

[0007] Furthermore, the pathogen is one or more of di(2-ethylhexyl) phthalate, cyclophosphamide, and tripterygium wilfordii glycosides.

[0008] The mechanism of astragaloside IV in treating oligoasthenozoospermia: Astragaloside IV treats oligoasthenozoospermia by improving the microenvironment of sperm.

[0009] Furthermore, the mechanism of astragaloside IV in treating oligoasthenozoospermia is as follows: astragaloside IV inhibits oxidative stress response, enhances the activity of antioxidant enzymes (such as superoxide dismutase and catalase), reduces the generation of free radicals, improves the microenvironment of sperm, and treats oligoasthenozoospermia.

[0010] Furthermore, the mechanism of astragaloside IV in treating oligoasthenozoospermia is as follows: astragaloside IV promotes the secretion of testosterone, improves the microenvironment of sperm, promotes the growth and maturation of sperm, and treats oligoasthenozoospermia.

[0011] Furthermore, the mechanism of astragaloside IV in treating oligoasthenozoospermia is as follows: astragaloside IV improves the microenvironment of sperms by regulating the secretion of follicle-stimulating hormone, promotes sperm growth, and treats oligoasthenozoospermia.

[0012] Furthermore, the mechanism of astragaloside IV in treating oligoasthenozoospermia is as follows: astragaloside IV improves the microenvironment of sperms by regulating the secretion of luteinizing hormone, promotes sperm growth, and treats oligoasthenozoospermia.

[0013] The second object of the present invention is a pharmaceutical preparation for treating oligoasthenospermia, comprising astragaloside IV.

[0014] Furthermore, the pharmaceutical preparation is an oral solution, an injection, a granule, a tablet, a pill, a powder, a capsule or a pellet.

[0015] In the present invention, astragaloside IV can also be made into a gel or a patch and directly applied to the skin to treat sperm syndrome by means of the skin absorption mechanism.

[0016] In the present invention, astragaloside IV can also be made into a spray for nasal administration.

[0017] Astragaloside IV can be combined with nano-carriers (such as nanoparticles, nanocapsules, liposomes) to develop nano-drug dosage forms. Nanotechnology is used to improve the bioavailability, drug efficacy and targeting of drugs. Nano-preparations can ensure that drugs act more effectively at the target location and improve the therapeutic effect by adjusting parameters such as particle size and drug loading.

[0018] Beneficial effects of the present invention:

[0019] The application of astragaloside IV in the preparation of a drug for treating oligoasthenozoospermia and the drug, through animal experiments, show that astragaloside IV significantly improves the quantity and quality of rat sperm, and no obvious side effects are observed during the treatment process. Astragaloside IV has the effects of inhibiting oxidative stress response, promoting the secretion of testosterone, regulating the secretion of follicle-stimulating hormone and luteinizing hormone, and can also promote the growth and maturation of sperm, effectively improve sperm function, and enhance the body's ability to repair testicular damage. Moreover, there are no obvious side effects during the treatment of oligoasthenozoospermia by astragaloside IV.

[0020] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 The experimental process diagram of SD rats according to the experimental method in the embodiment of the present invention is shown;

[0023] Figure 2 Shown are sperm testicular morphology of rats in each group and HE staining of testicular and epididymal tissues in the experimental method of an embodiment of the present invention; Figure 2 A in the middle is the testicular morphology of rats in each group; Figure 2 B is the HE staining picture of rat testis tissue, and C is the HE staining picture of rat epididymis tissue in each group;

[0024] Figure 3 Shown are the sperm count and morphology of each group of rats according to an embodiment of the present invention;

[0025] Figure 4 The morphology of spermatozoa in rats of the model group according to an embodiment of the present invention is shown;

[0026] Figure 5 A graph showing the content of testosterone and follicle stimulating hormone in the serum of each group of rats according to an embodiment of the present invention is shown; Figure 5 A is a graph showing the testosterone content in the serum of rats in each group; Figure 5 Middle B is the content of follicle stimulating hormone in the serum of rats in each group;

[0027] Figure 6 A graph showing the content of luteinizing hormone in the serum of rats in each group according to an embodiment of the present invention is shown;

[0028] Figure 7 Shown are graphs of sperm count and motility of rats in various groups according to an embodiment of the present invention; Figure 7 A in the middle is the sperm count of rats in each group. Figure 7 Middle B is the sperm motility graph of rats in each group;

[0029] Figure 8 The content diagram of MDA and GSH / GSSG in the testicular tissue of each group of rats according to the embodiment of the present invention is shown; Figure 8 A in the middle is the MDA content in rat testicular tissue. Figure 8 Middle B is the graph of GSH / GSSG content in rat testicular tissue;

[0030] Fig. 9 The content of GSH-PX and GST in the testicular tissue of each group of rats according to the embodiment of the present invention is shown; Fig. 9 A in the middle is the content of GSH-PX in rat testicular tissue. Fig. 9 Middle B is the graph of GST content in rat testicular tissue; DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Animal Experimentation:

[0033] (1) Experimental animals

[0034] Male SD rats, weighing 200-220 g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. License No.: SCXK (Liao) 2020-0001. Rats were allowed to drink water and eat freely. The bedding and water in the cage were changed every day to keep it dry and clean.

[0035] (2) Experimental methods

[0036] 60 SPF SD male rats were divided into 6 groups. 40 rats were randomly selected for 8 consecutive weeks. The other 10 mice were allowed to drink distilled water freely. The general condition of the rats was observed daily. 10 rats without modeling were used as the normal control group, and the 60 rats with successful modeling were randomly divided into the normal group, the model group (DEHP (English abbreviation for di(2-ethylhexyl) phthalate) gavage), and the animals in each group were given the drug according to the dose. The control group was intraperitoneally injected with normal saline at 120 mg / kg body weight, and the model group and each treatment group were gavaged with DEHP at 60 mg / kg body weight, once a day for 28 consecutive days. Starting from the 29th day, the rats in the low, medium and high doses of Chinese medicine treatment groups were intraperitoneally injected with astragaloside IV solution (abbreviated as AS-IV, preparation of astragaloside IV solution: dissolve astragaloside IV in ethanol (generally 100 mg astragaloside IV is dissolved in 300 microliters of ethanol), and then diluted with physiological salt to the corresponding dose concentration) according to their body weight, with doses of 1 mg / kg, 10 mg / kg and 20 mg / kg respectively, and the control group and model group were gavaged with equal volumes of pure water for 14 consecutive days. During the administration period, the rats were weighed once a week, and the gavage dose was adjusted according to the new body weight. Blood was collected (abdominal aorta) between 07:00 and 09:00 on the morning of the second day after the end; after the rats were anesthetized with chloral hydrate, the testicles, epididymis and other tissues were quickly removed, and the operation was carried out on ice to remove the adhesion of blood vessels, ligaments and fat tissues for use; among them, the experimental process of SD rats (DEHP gavage for four weeks, astragaloside IV intraperitoneal injection for 2 weeks) is shown in the figure Figure 1 shown.

[0037] Evaluation indicators and effect evaluation:

[0038] (1) Weight monitoring and calculation of testicular and epididymal indexes

[0039] After the rats were dissected, the testicles and epididymis were separated and weighed on an electronic balance, and the visceral fat coefficient, testicular and epididymal index of each group of rats were calculated. Figure 2 As shown in A, in this figure, from left to right, there are the testicular morphology of sperm in the control group, the testicular morphology of sperm in the model group, the testicular morphology of sperm in the low-dose AS-Ⅳ group, the testicular morphology of sperm in the medium-dose AS-Ⅳ group, and the testicular morphology of sperm in the high-dose AS-Ⅳ group. Figure 2 As shown in Figure A, AS-Ⅳ promoted the growth of rat sperm testis damaged by DEHP and restored its pre-damage morphology.

[0040] Morphological examination of epididymis and testis in oligospermia model rats

[0041] The testis and epididymis tissues of the rats in the experimental group and the control group were photographed and paraffin sections were prepared and HE staining was performed. Among them, HE staining was used to evaluate the effect of AS-Ⅳ on the histological changes of the testis and epididymis of rats. Figure 1 Shown in B (magnification ×200) and C (magnification ×20). Figure 2 B is a section of rat testis tissue. Figure 2 Middle C is a section of rat epididymis;

[0042] from Figure 2 As shown in Figures B and C, the testicular tissue structure of the rats in the control group was intact, with a large number of sperm cells, which were concentrated in the center of the seminiferous tubule lumen. The seminiferous tubules were evenly distributed and dense, without atrophy. The tubular membrane was smooth, complete, and of normal thickness. The supporting cells and spermatogenic cells at all levels were arranged regularly and in rich layers. There were a large number of mature sperm in the lumen. The number of sperm in the epididymal tubules of the rats in the model group was scarce and diffusely distributed. The seminiferous tubules in the model group were atrophic, the interstitial cells were significantly shed, the tubular membrane was thickened, the number of cell layers decreased, and the number of mature sperm in the lumen was small. In addition, in the epididymal head of the rats in the control group, the sperm cells filled the entire lumen; while in the epididymal head of the rats in the model group, the sperm cells were distributed on one side of the lumen. Figure 2 Figures B and C confirmed that DEHP can cause a decrease in the number of sperm cells in male rats. After intervention with different doses of astragaloside IV, the lumen of the seminiferous tubules, the thickness of the tubule membrane, the number of cell layers, and the number of spermatogenic cells were improved to varying degrees.

[0043] (2) Sperm quality evaluation

[0044] Wash the epididymis, remove the fat tissue, and place it in a beaker containing 1 mL of 37°C preheated physiological saline. Use ophthalmic scissors to make 6-8 cuts along the tail of the epididymis, and incubate it in a 37°C water bath incubator for 10 minutes to allow the sperm to escape from the tail of the epididymis. Filter the sperm suspension with a 300-mesh filter and keep the temperature at 37°C. Dip a drop of sperm suspension into the counting pool in the center of the Markler sperm counting plate and observe the number of sperm (n) in a 10×10 square grid with a 200x optical microscope. The number of sperm per milliliter is n×10. 6 Each rat was observed three times, one column of squares was observed each time, the total number of sperm was counted, and the sperm motility was calculated, the survival rate / % = (a+b+c) / (a+b+c+d)×100%; the number of sperm moving forward was counted, and the sperm motility was calculated, the motility / % = (a+b) / (a+b+c+d)×100%.

[0045] The effects of astragaloside IV on sperm count and morphology in rats with spermatogenesis impairment experimental model are detailed in Figure 3 and Figure 4 , Figure 3The figure shows the sperm count and morphology of rats in each group. Compared with the sperm of rats in the control group, the sperm count of the DEHP model group was significantly reduced and abnormal sperm appeared. However, with the increase of the concentration of astragaloside IV, the sperm count gradually returned to normal. Figure 4 This is the morphology of sperm in the DEHP model group. DEHP can cause sperm deformities in rats. From left to right, they are double-tailed sperm, headless sperm, small-headed sperm and curled-tailed sperm.

[0046] Results of sperm count and sperm motility are as follows Figure 7 As shown, Figure 7 A in the middle is the sperm count of rats in each group. Figure 7 B is the sperm motility diagram of rats in each group. Figure 7 The comparison of the number and motility of sperm in each group of rats showed that compared with the number and motility of sperm in the model group, the number and motility of sperm in the low-dose, medium-dose and high-dose groups injected with astragaloside IV were improved, among which the number and sperm of rats in the high-dose group recovered most significantly, close to the level of sperm and number in the control group, indicating that astragaloside IV helps to treat oligospermia in rats damaged by DEHP, promotes sperm production, and improves the number and motility of sperm. Data are expressed as mean ± standard deviation (n = 3).

[0047] (3) Detection of serum sex hormone levels in rats

[0048] After centrifugation, the rat serum was taken and the levels of testosterone (T), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and other hormones were measured using the ELISA kit instructions. Figure 4-5 As shown. Figure 5 A in the figure is the testosterone content in rat serum. Figure 5 B is the content of follicle stimulating hormone in rat serum. Figure 6 This is a graph showing the luteinizing hormone content in rat serum.

[0049] from Figure 5 and Figure 6 It can be seen that compared with the control group, the T content in the serum of the model group rats was lower than that of the control group due to the effect of DEHP, and the FSH and LH contents in the serum of the rats were higher than those of the control group. The T content in the serum of the rats in the low-dose, medium-dose and high-dose groups injected with astragaloside IV was significantly increased, among which the T content in the serum of the rats in the high-dose group was close to that of the control group, indicating that astragaloside IV can promote the secretion of testosterone in rats after the effect of DEHP, improve the microenvironment of sperm in rats after the effect of DEHP, promote the growth and maturation of sperm, and treat oligoasthenospermia.

[0050] The levels of FSH and LH in the serum of rats in the low-dose, medium-dose and high-dose groups injected with astragaloside IV gradually decreased, among which the levels of FSH and LH in the serum of rats in the high-dose group were close to those in the control group. This also shows that astragaloside IV can regulate the secretion of follicle-stimulating hormone and luteinizing hormone in rats after the action of DEHP, improve the microenvironment of sperm in rats after the action of DEHP, promote the growth and maturation of sperm, and treat oligoasthenospermia.

[0051] (4) Detection of oxidative stress level in rat testicular tissue

[0052] ELISA method was used to detect the oxidative stress level indicators of testis / epididymis tissue: MDA (Malondialdehyde), GSH (Glutathione), T-GSH, GSH / GSSG (GSSG is called oxidized glutathione) Glutathione S-transferase (glutathione S transferase), GSH-PX (Glutathione Peroxidase) and GST (Glutathione S-transferase). After collecting the testis / epididymis of rats, they were homogenized in an ice bath according to the ratio of tissue mass (g): extract volume (mL) = 1:5-1:10; centrifuged at 4°C (8000g for 10 minutes), the supernatant was taken and placed on ice for later use. The test results are as follows Figure 8-9 shown.

[0053] in, Figure 8 A in the middle is the MDA content in rat testicular tissue. Figure 8 B is the graph of GSH / GSSG content in rat testicular tissue. Fig. 9 A in the middle is the content of GSH-PX in rat testicular tissue. Fig. 9 Middle B is the graph of GST content in rat testicular tissue.

[0054] Figure 5-Figure 9 Data are expressed as mean ± standard deviation (n = 3). The significant differences between the Vcon group (control group) and other groups are: *P < 0.05, **P < 0.01, ***P < 0.001. T: testosterone; FSH: follicle stimulating hormone; LH: luteinizing hormone.

[0055] in, Figure 8 A in the middle is the MDA concentration of testicular tissue of rats in each group. Figure 8 Figure B shows the GSH / GSSG content in the testicular tissue of rats in each group. Figure 8It can be seen that compared with the values ​​of the control group, the levels of MDA and GSH / GSSG in the testicular tissue of the rats in the model group were significantly increased, and the oxidative stress indicators MDA and GSH / GSSG of the rats in the low-dose, medium-dose and high-dose groups injected with astragaloside IV were reduced. Among them, the oxidative stress indicators of rats in the medium-dose and high-dose groups were close to the levels of rats in the control group, which means that astragaloside IV can reduce the level of oxidative stress and play a certain antioxidant effect.

[0056] Fig. 9 A in the middle is the concentration of GSH-PX in the testicular tissue of rats in each group. Fig. 9 Figure B shows the GST content in the testicular tissue of rats in each group. Fig. 9 It can be seen that compared with the values ​​in the control group, the levels of GSH-PX and GST in the testicular tissue of the rats in the model group were significantly decreased, and the oxidative stress indexes GSH-PX and GST of the rats in the low-dose, medium-dose and high-dose groups injected with astragaloside IV were increased. Among them, the oxidative stress index of the rats in the low-, medium- and high-dose groups of GSH-PX were close to the levels of the rats in the control group, and the GST levels of the rats in the medium- and high-dose astragaloside IV groups were restored to levels close to those of the rats in the control group, which means that astragaloside IV can restore the oxidative stress level of DEHP rats and play a certain antioxidant effect.

[0057] In summary, from Figure 5-Figure 9 It can be seen that compared with the control group, the sperm count in the model group decreased and the deformity rate increased; the levels of FSH and LH were significantly increased (P < 0.01); the T level was significantly decreased (P < 0.01), indicating that DEHP can successfully construct a rat oligospermia model, and high-dose astragaloside IV can indeed significantly increase the T level in rat serum and reduce the content of FSH and LH to a certain extent. Glutathione depletion and lipid peroxidation are important indicators of oxidative stress. GPX catalyzes the oxidation of GSH to oxidized GSH (GSSG), and GSSG is recycled through NADPH to generate reduced GSH. Glutathione is synthesized from L-glutamate, L-cysteine ​​and glycine through γ-glutamylcysteine ​​and glutathione synthetase. However, the redox reaction is catalyzed by GSH-dependent enzymes, including GSH-PX and glutaredoxins. MDA is an indicator reflecting lipid peroxidation and a marker of DNA damage induced by oxidative stress. This result proves that astragaloside IV can play a certain role in intervention and treatment of oligoasthenozoospermia SD rats caused by DEHP. At the same time, it shows that astragaloside IV can regulate the oxidative stress and glutathione metabolism-related indicators MDA, T-GSH, GSH / GSSG, GSH-PX and GST of the testis of oligoasthenozoospermia rats to play a role in treating oligoasthenozoospermia.

[0058] Astragaloside IV can protect sperm by reducing oxidative free radicals and oxidative stress reactions in the body. Oxidative stress is an important factor leading to the decline of sperm quality. Excessive free radicals can damage the sperm membrane and reduce the vitality and function of sperm. Astragaloside IV improves sperm quality by enhancing the activity of antioxidant enzymes (such as superoxide dismutase and catalase) and reducing the generation of free radicals. Astragaloside IV can inhibit oxidative stress and improve the survival rate and activity of sperm.

[0059] Astragaloside IV can regulate the endocrine system and promote the secretion of male hormones (such as testosterone), thereby supporting the growth and maturation of sperm. By regulating the secretion of FSH and LH, astragaloside IV helps to restore the normal balance of reproductive hormones and promote sperm production.

[0060] In summary, astragaloside IV significantly improved the quantity and quality of rat sperm, and no obvious side effects were observed during the treatment. In addition, astragaloside IV has antioxidant and hormone balance regulating effects in the treatment of oligoasthenozoospermia. Compared with traditional single mechanism treatment (such as hormone replacement therapy or simple antioxidant therapy), it can provide more comprehensive therapeutic effects and significantly improve the clinical symptoms of oligoasthenozoospermia.

[0061] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Application of astragaloside IV in the preparation of drugs for treating oligoasthenospermia.

2. The use according to claim 1, characterized in that: The oligoasthenozoospermia is caused by a pathogen.

3. The use according to claim 2, characterized in that: The pathogenic substance is one or more of di(2-ethylhexyl) phthalate, cyclophosphamide, and tripterygium wilfordii glycosides.

4. The use according to claim 1, characterized in that: The astragaloside IV treats oligoasthenospermia by improving the microenvironment of sperm.

5. The use according to claim 4, characterized in that: The astragaloside IV can treat oligoasthenospermia by inhibiting oxidative stress reaction, reducing the generation of free radicals, improving the microenvironment of sperm.

6. The use according to claim 4, characterized in that: The astragaloside IV promotes the secretion of testosterone, improves the microenvironment of sperm, promotes the growth and maturation of sperm, and treats oligoasthenospermia.

7. The use according to claim 4, characterized in that: The astragaloside IV improves the microenvironment of sperms by regulating the secretion of follicle-stimulating hormone, promotes the growth of sperms, and treats oligoasthenospermia.

8. The use according to claim 4, characterized in that: The astragaloside IV improves the microenvironment of sperms by regulating the secretion of luteinizing hormone, promoting the growth of sperms, and treating oligoasthenospermia.

9. A pharmaceutical preparation for treating oligoasthenozoospermia, characterized in that: Including astragaloside IV.

10. The pharmaceutical preparation according to claim 9, characterized in that The pharmaceutical preparation is oral solution, injection, granule, tablet, pill, powder, capsule or dripping pill.

Images